Journal
BRITISH JOURNAL OF CANCER
Volume 92, Issue 5, Pages 942-948Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6602376
Keywords
methylation; SPARC; lung cancer; immunostaining
Categories
Funding
- NCI NIH HHS [P50 CA070907, P50CA70907] Funding Source: Medline
Ask authors/readers for more resources
SPARC (secreted protein acidic and rich in cysteine) is an extracellular Ca2+-binding matricellular glycoprotein associated with the regulation of cell adhesion and growth. We investigated loss of expression of SPARC gene and promoter methylation in lung cancers and correlated the data with clinicopathological features. We observed loss of SPARC expression in 12 of 20 (60%) lung cancer cell lines. Treatment of expression-negative cell lines with a demethylating agent restored expression in all cases. Methylation frequencies of SPARC gene were 55% in 20 lung cancer cell lines. Primary tumours had methylation at a rate of 69% (119 of 173), while nonmalignant lung tissues (n = 60) had very low rates (3%). In lung adenocarcinomas, SPARC methylation correlated with a negative prognosis (P = 0.0021; relative risk 4.65, 95% confidence interval 1.75-12.35, multivariate Cox's proportional-hazard model). Immunostaining revealed protein expression in bronchial epithelium (weak intensity) and in juxtatumoral stromal tissues (strong intensity) accompanied by frequent loss in cancer cells that correlated with the presence of methylation (P<0.001). Our findings are of biological interest and potentially of clinical importance in human lung cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available